Please read Drs. Strom and Roy’s article in the Pharmacoepidemiology and Drug Safety titled, “Validation of a claims-based algorithm for identifying non-infectious pneumonitis in patients diagnosed with lung cancer.“
Lung cancer is the leading cause of cancer death in both men and women in the United States. Development of novel medications and therapeutic strategies to treat lung cancer, including programmed cell death-1, programmed death-ligand 1, cytotoxic T-lymphocyte-associated protein 4 blockade, and use of targeted radiation to treat oligometastatic disease, have brought hope to patients who previously had few therapeutic options. These benefits, however, have not been without costs, as adverse events often impact quality of life and may result in the premature cessation of therapy, which can reduce the effectiveness of these approaches. To read the full article.
Validation of a claims-based algorithm for identifying non-infectious pneumonitis in patients diagnosed with lung cancer. Neibart SS, Portal DE, Malhotra J, Jabbour SK, Roy JA, Strom BL.Pharmacoepidemiol Drug Saf. 2021 Aug 11. PMID: 34378828 DOI: 1002/pds.5339 Online ahead of print.